AllSci News
MeiraGTx to use ZipBio’s AI platform for geographic atrophy therapies
US-based firms ZipBio and MeiraGTx (Nasdaq: MGTX) entered into a strategic licensing agreement under which MeiraGTx will obtain exclusive rights to ZipBio’s…
SK Bioscience takes global rights to Gates MRI’s RSV antibody
SK Boscience revealed an exclusive licensing agreement with the Gates Medical Research Institute (Gates MRI) granting SK rights to develop and commercialize…
Pfizer/Metsera GLP-1 RA shows sustained weight loss with monthly dosing in Phase IIb
Pfizer announced positive topline results from the Phase IIb VESPER-3 trial evaluating its investigational, ultra-long-acting injectable GLP-1 receptor agonist PF-08653944 (also referred…
Menarini’s Insilico-sourced KIF18A inhibitor reaches first-in-human milestone
Insilico Medicine revealed that the novel small molecule MEN2501, developed through Insilico’s generative AI drug discovery platform, has been dosed in a…
SciSparc Secures US Patent for Cannabinoid-Enhanced Antimicrobial Technology Against MRSA
NeuroThera Labs, a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), has been granted a significant U.S. patent covering a novel cannabinoid-enhanced platform designed to combat antimicrobial resistance, particularly against challenging pathogens like Methicillin-resistant Staphylococcus aureus (MRSA). The United States Patent and Trademark Office issued the patent, which protects a groun
Actinogen’s Xanamem Phase IIb XanaMIA trial shows potential in Alzheimer’s
Australia-based Actinogen Medical announced positive interim findings from the ongoing Phase IIb XanaMIA trial evaluating Xanamem, an oral inhibitor of 11β-hydroxysteroid dehydrogenase…
Novo Nordisk’s CagriSema outperforms semaglutide in Phase III REIMAGINE 2 diabetes trial
Novo Nordisk posted Phase III data showing that its next pipeline obesity hope CagriSema, a fixed-dose injectable of the amylin receptor agonist…
Skye Bioscience Nimacimab and Semaglutide Combination Demonstrates 22.3% Weight Loss in Phase 2a Trial
Skye Bioscience [announced](https://www.globenewswire.com/news-release/2026/02/02/3230132/0/en/Skye-Reports-Positive-CBeyond-Phase-2a-Extension-Interim-Study-Results-for-Nimacimab-in-Combination-With-Semaglutide.html) positive clinical trial results for nimacimab, a peripherally-restricted CB1 inhibitor antibody, when combined with semaglutide in treating obesity. The Phase 2a CBeyond study demons
AdvanCell licenses 48Hour Discovery peptide Lead-212 radiotherapeutic for GI cancer
AdvanCell unveiled a collaboration and exclusive licensing agreement with 48Hour Discovery that grants AdvanCell worldwide rights to develop a peptide-based Lead-212 radiotherapeutic…
Pharming faces US FDA’s CRL for pediatric Joenja supplemental filing
The Netherlands-based Pharming Group said the US FDA issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) seeking…
Anaphylm’s FDA review stalls as Aquestive faces critical packaging challenges
Aquestive Therapeutics Inc., (NASDAQ: AQST) revealed that the US FDA issued a Complete Response Letter (CRL) for its New Drug Application (NDA)…
SanegeneBio and Genentech strike USD 1.5b global RNAi collaboration
SanegeneBio, a clinical-stage biotechnology company based in Masschusetts with significant presence in China, announced a global licensing agreement with Roche Group member…
GSK hands back RNA drug from collaboration with Wave Life Sciences
Massachusetts-based biotech Wave Life Sciences revealed it has regained full global rights to WVE-006, a GalNAc-conjugated RNA editing therapeutic candidate for alpha-1…
vTv Therapeutics expands PDE4i deal with Newsoara to global rights
US-based vTv Therapeutics granted China-based Newsoara Biopharma Co., Ltd an exclusive worldwide license to develop and commercialize its orally administered PDE4 inhibitor…
Sanofi’s venglustat hits Phase III endpoints in Gaucher disease, but misses on Fabry
Sanofi announced positive topline results from the global Phase III LEAP2MONO study evaluating its investigational oral glucosylceramide synthase inhibitor venglustat in patients…
The AllSci Brief
Free, systematic R&D and deal news. Daily.